{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:02:54Z","timestamp":1777395774964,"version":"3.51.4"},"reference-count":46,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2019,10,15]]},"DOI":"10.3233\/jad-190288","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T11:51:04Z","timestamp":1568116264000},"page":"1297-1308","source":"Crossref","is-referenced-by-count":8,"title":["Impact of Anti-Dementia Medication on the Risk of Death and Causes of Death in Alzheimer\u2019s Disease"],"prefix":"10.1177","volume":"71","author":[{"given":"Miika","family":"Linna","sequence":"first","affiliation":[{"name":"Aalto University\/Health Care, Engineering, Management and Architecture (HEMA), Aalto, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sauli","family":"Vuoti","sequence":"additional","affiliation":[{"name":"Merck Sharpe & Dohme (MSD), Espoo, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katariina","family":"Silander","sequence":"additional","affiliation":[{"name":"Aalto University\/Health Care, Engineering, Management and Architecture (HEMA), Aalto, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iiris","family":"H\u00f6rhammer","sequence":"additional","affiliation":[{"name":"Aalto University\/Health Care, Engineering, Management and Architecture (HEMA), Aalto, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olli","family":"Halminen","sequence":"additional","affiliation":[{"name":"Aalto University\/Health Care, Engineering, Management and Architecture (HEMA), Aalto, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teija","family":"Mikkola","sequence":"additional","affiliation":[{"name":"Finnish Local and Regional Authorities, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e4ivi","family":"Koivuranta-Vaara","sequence":"additional","affiliation":[{"name":"Finnish Local and Regional Authorities, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauri J.","family":"Virta","sequence":"additional","affiliation":[{"name":"Research Department, Social Insurance Institution of Finland, Turku, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirkka","family":"Koivusalo","sequence":"additional","affiliation":[{"name":"MedEngine, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tero","family":"Ylisaukko-oja","sequence":"additional","affiliation":[{"name":"MedEngine, Helsinki, Finland"},{"name":"University of Oulu, Center for Life Course Health Research, Oulu, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-190288_ref1","doi-asserted-by":"crossref","unstructured":"(2016) 2016 Alzheimer\u2019s disease facts and figures., Alzheimers Dement 12, 459\u2013509.","DOI":"10.1016\/j.jalz.2016.03.001"},{"key":"10.3233\/JAD-190288_ref2","unstructured":"Prince M , Wimo A , Guerchet M , Ali GC , Wu Y PA (2015) World Alzheimer Report 2015: The global impact of dementia. An analysis of prevalence, incidence, costs and trends., Alzheimer\u2019s Disease International, London."},{"key":"10.3233\/JAD-190288_ref3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer\u2019s disease and other dementias: A priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-190288_ref4","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7326\/0003-4819-140-7-200404060-00008","article-title":"Survival after initial diagnosis of Alzheimer disease","volume":"140","author":"Larson","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.3233\/JAD-190288_ref5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JAD-2012-120808","article-title":"Risk of death among persons with Alzheimer\u2019s disease: A national register-based nested case-control study","volume":"33","author":"Lonnroos","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190288_ref6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000367783","article-title":"A systematic review and meta-analysis examining pneumonia-associated mortality in dementia","volume":"39","author":"Foley","year":"2015","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-190288_ref7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12883-014-0173-4","article-title":"Response to cholinesterase inhibitors affects lifespan in Alzheimer\u2019s disease","volume":"14","author":"Wattmo","year":"2014","journal-title":"BMC Neurol"},{"key":"10.3233\/JAD-190288_ref8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000362926","article-title":"Risk factors that affect life expectancy in Alzheimer\u2019s disease: A 15-year follow-up","volume":"38","author":"Wattmo","year":"2014","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.3233\/JAD-190288_ref9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ana.20100","article-title":"Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum","volume":"55","author":"Mesulam","year":"2004","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-190288_ref10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jalz.2012.09.015","article-title":"Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer\u2019s disease","volume":"9","author":"Zhu","year":"2013","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-190288_ref11","first-page":"391","article-title":"Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer\u2019s disease","volume":"10","author":"Hager","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.3233\/JAD-190288_ref12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/JAD-170518","article-title":"Economic burden, mortality, and institutionalization in patients newly diagnosed with Alzheimer\u2019s disease","volume":"61","author":"Black","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190288_ref13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JAD-180843","article-title":"France will no more reimburse available symptomatic drugs against Alzheimer\u2019s disease","volume":"66","author":"Krolak-Salmon","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190288_ref14","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.3233\/JAD-132639","article-title":"Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer\u2019s disease and vascular dementia","volume":"42 Suppl 3","author":"Versijpt","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190288_ref15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2165\/11631830-000000000-00000","article-title":"Economic evaluation of treatment options in patients with Alzheimer\u2019s disease: A systematic review of cost-effectiveness analyses","volume":"72","author":"Pouryamout","year":"2012","journal-title":"Drugs"},{"key":"10.3233\/JAD-190288_ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10010","article-title":"The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer\u2019s disease","volume":"10","author":"Loveman","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.3233\/JAD-190288_ref17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/gps.4745","article-title":"The cost-effectiveness implications of suboptimal treatment for different severities of Alzheimer\u2019s disease in the UK","volume":"33","author":"Zala","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.3233\/JAD-190288_ref18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12877-018-0748-9","article-title":"Potential cost savings to be made by slowing cognitive decline in mild Alzheimer\u2019s disease dementia using a model derived from the UK GERAS observational study","volume":"18","author":"Lenox-Smith","year":"2018","journal-title":"BMC Geriatr"},{"key":"10.3233\/JAD-190288_ref19","unstructured":"Helsinki: The Finnish Medical Society Duodecim, Dementia. Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim, Finnish Neurological Society, Finnish Psychogeriatric Society, and Finnish Association for General Practice., Last updated 2017, Accessed on 2017."},{"key":"10.3233\/JAD-190288_ref20","unstructured":"Statistics Finland 2016: Population."},{"key":"10.3233\/JAD-190288_ref21","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/eht182","article-title":"The use of cholinesterase inhibitors and the risk of myocardial infarction and death: A nationwide cohort study in subjects with Alzheimer\u2019s disease","volume":"34","author":"Nordstrom","year":"2013","journal-title":"Eur Heart J"},{"key":"10.3233\/JAD-190288_ref22","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jalz.2018.02.011","article-title":"Acetylcholinesterase inhibitors and risk of stroke and death in people with dementia","volume":"14","author":"Tan","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-190288_ref23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/ageing\/afx098","article-title":"Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer\u2019s disease: A retrospective survival analysis","volume":"47","author":"Mueller","year":"2018","journal-title":"Age Ageing"},{"key":"10.3233\/JAD-190288_ref24","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40264-014-0161-z","article-title":"Cardiovascular effects of drugs used to treat Alzheimer\u2019s disease","volume":"37","author":"Howes","year":"2014","journal-title":"Drug Saf"},{"key":"10.3233\/JAD-190288_ref25","first-page":"e274","article-title":"Representation of patients with dementia in clinical trials of donepezil","volume":"11","author":"Gill","year":"2004","journal-title":"Can J Clin Pharmacol"},{"key":"10.3233\/JAD-190288_ref26","doi-asserted-by":"crossref","first-page":"e1000157","DOI":"10.1371\/journal.pmed.1000157","article-title":"Cholinesterase inhibitors and hospitalization for bradycardia: A population-based study","volume":"6","author":"Park-Wyllie","year":"2009","journal-title":"PLoS Med"},{"key":"10.3233\/JAD-190288_ref27","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/j.1532-5415.2009.02488.x","article-title":"Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system","volume":"57","author":"Hernandez","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-190288_ref28","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1111\/j.1532-5415.2012.04241.x","article-title":"Comparative cardiovascular safety of dementia medications: A cross-national study","volume":"60","author":"Fosbol","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-190288_ref29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","article-title":"Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study","volume":"169","author":"Gill","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.3233\/JAD-190288_ref30","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1345\/aph.1K139","article-title":"Evaluation of centrally acting cholinesterase inhibitor exposures in adults","volume":"41","author":"McCain","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.3233\/JAD-190288_ref31","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pds.1746","article-title":"Drug-induced torsades de pointes: Data mining of the public version of the FDA Adverse Event Reporting System (AERS)","volume":"18","author":"Poluzzi","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.3233\/JAD-190288_ref32","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2169\/internalmedicine.48.2181","article-title":"Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes","volume":"48","author":"Tanaka","year":"2009","journal-title":"Intern Med"},{"key":"10.3233\/JAD-190288_ref33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.39020.710602.47","article-title":"Calculate the QT interval in patients taking drugs for dementia","volume":"335","author":"Leitch","year":"2007","journal-title":"BMJ"},{"key":"10.3233\/JAD-190288_ref34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1345\/aph.1K514","article-title":"Prolonged QT interval, syncope, and delirium with galantamine","volume":"42","author":"Fisher","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.3233\/JAD-190288_ref35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1567205043332009","article-title":"Cardiac effect of cholinesterase inhibitors used in Alzheimer\u2019s disease\u2013from basic research to bedside","volume":"1","author":"Masuda","year":"2004","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-190288_ref36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2377-14-101","article-title":"Early intervention in Alzheimer\u2019s disease: A health economic study of the effects of diagnostic timing","volume":"14","author":"Barnett","year":"2014","journal-title":"BMC Neurol"},{"key":"10.3233\/JAD-190288_ref37","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3233\/JAD-180983","article-title":"Relationship between treatment initiation and healthcare costs in Alzheimer\u2019s disease","volume":"68","author":"Black","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190288_ref38","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/jgs.15415","article-title":"Cardiovascular outcomes of cholinesterase inhibitors in individuals with dementia: A meta-analysis and systematic review","volume":"66","author":"Isik","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"10.3233\/JAD-190288_ref39","doi-asserted-by":"crossref","first-page":"29266","DOI":"10.1038\/srep29266","article-title":"Association between acetylcholinesterase inhibitors and risk of stroke in patients with dementia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-190288_ref40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/147323000603400401","article-title":"Cholinesterase inhibitors in the clinical management of Alzheimer\u2019s disease: Importance of early and persistent treatment","volume":"34","author":"Seltzer","year":"2006","journal-title":"J Int Med Res"},{"key":"10.3233\/JAD-190288_ref41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-510X(03)00229-6","article-title":"The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer\u2019s disease and vascular dementia","volume":"216","author":"Lojkowska","year":"2003","journal-title":"J Neurol Sci"},{"key":"10.3233\/JAD-190288_ref42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jalz.2010.07.001","article-title":"An economic evaluation of early assessment for Alzheimer\u2019s disease in the United Kingdom","volume":"8","author":"Getsios","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-190288_ref43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"The Lancet Neurology Commission Defeating Alzheimer\u2019s disease and other dementias: A priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-190288_ref44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3233\/JAD-150692","article-title":"Timely diagnosis for Alzheimer\u2019s disease: A literature review on benefits and challenges","volume":"49","author":"Dubois","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-190288_ref45","doi-asserted-by":"crossref","first-page":"e012100","DOI":"10.1136\/bmjopen-2016-012100","article-title":"Cohort profile: The Finnish Medication and Alzheimer\u2019s disease (MEDALZ) study","volume":"6","author":"Tolppanen","year":"2016","journal-title":"BMJ Open"},{"key":"10.3233\/JAD-190288_ref46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000437050","article-title":"Longitudinal associations between survival in Alzheimer\u2019s disease and cholinesterase inhibitor use, progression, and community-based services","volume":"40","author":"Wattmo","year":"2015","journal-title":"Dement Geriatr Cogn Disord"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-190288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:06:43Z","timestamp":1777370803000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-190288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":46,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-190288","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]}}}